Business Context and Reporting Period
Company: Palatin Technologies, Inc. (PTN)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three and six months ended December 31, 2025
Business Overview: Palatin is a biopharmaceutical company developing first-in-class medicines targeting the melanocortin receptor (MCR) system. Key programs include MC4R agonists for obesity and rare neuroendocrine diseases, and MC1R agonists for ocular and inflammatory diseases. The company recently completed a 1-for-50 reverse stock split in August 2025.
Key Financial Metrics
| Metric | Six Months Ended Dec 31, 2025 | Six Months Ended Dec 31, 2024 |
|---|---|---|
| Revenues | $8,963,586 | $0 |
| Net Loss | $(2,586,327) | $(10,266,131) |
| Net Loss Per Share (Basic/Diluted) | $(1.47) | $(25.36) |
| Cash and Cash Equivalents (Dec 31, 2025) | $14,476,162 | $2,564,265 (June 30, 2025) |
| Current Liabilities | $6,332,648 | $8,010,030 (June 30, 2025) |
| Accumulated Deficit | $(461,660,226) | $(459,073,899) (June 30, 2025) |
| Operating Cash Flow | $(6,426,227) | $(11,863,319) |
| Financing Cash Flow | $18,350,940 | $3,252,527 |
Material Changes vs. Prior Period
- Revenue Surge: Revenue increased from $0 to $8.96 million for the six-month period, driven entirely by a new agreement with Boehringer Ingelheim (BI). This included $2.34 million for patent assignment, $6.49 million for a research milestone, and $133,586 in FTE reimbursements.
- Reduced Net Loss: Net loss improved significantly to $2.59 million from $10.27 million in the prior year period, primarily due to the new revenue stream and a reduction in R&D spending on MCR programs.
- Liquidity Improvement: Cash balances increased from $2.56 million to $14.48 million, fueled by $16.9 million in equity financing proceeds and $1.46 million from warrant exercises.
- Stock Structure: A 1-for-50 reverse stock split was effective August 11, 2025. All share and per-share data in the filing have been retroactively adjusted.
Guidance, Outlook, and Risks
- Outlook: Management expects existing cash ($14.5 million) to fund operations for the next 12 months. The company anticipates incurring losses for the foreseeable future and may never achieve profitability.
- Pipeline Milestones:
- PL7737 (Oral MC4R agonist): IND filing projected in H1 2026.
- Novel Weekly MC4R Peptide: IND filing projected in H2 2026.
- PL8177 (Ulcerative Colitis): Reported positive Phase 2 topline data in Q1 2025.
- Recent Agreements:
- Boehringer Ingelheim: Assigned IP for retinal disease peptides; potential for up to $307 million in future milestones.
- Altanispac Labs (Subsequent Event): Jan 8, 2026 sublicense of PL9643 (dry eye) for $3.8 million in debt cancellation, to be recognized as revenue in Q1 2026.
- Risks:
- Liquidity: Continued dependence on additional financing; ability to raise future funds is not considered probable under current accounting standards.
- Regulatory: Risks associated with FDA delays, government shutdowns, and clinical trial failures.
- Legal: Settled a breach of contract claim with H.C. Wainwright & Co. in November 2025 for $500,000 cash and warrants.
Investor Verification Checklist
- Cash Runway: Verify if the $14.5 million cash balance is sufficient to reach the projected H1/H2 2026 IND filings given current burn rates.
- Revenue Recognition: Confirm the timing and probability of future milestone payments from Boehringer Ingelheim, as current revenue is heavily front-loaded.
- Dilution Impact: Assess the impact of outstanding warrants (including Series J and K with FDA-linked expiration) and the recent equity offerings on future share count.
- Debt Cancellation: Verify the accounting treatment and future revenue recognition of the $3.8 million Altanispac debt cancellation.
- Reverse Split Compliance: Ensure all historical data comparisons account for the 1-for-50 reverse stock split.